What's Happening?
Ryght AI has announced a partnership with Biorasi, a clinical research organization, to improve feasibility accuracy in clinical trials using AI technology. Ryght AI's platform creates dynamic digital twins of research sites, enabling faster site selection and streamlined workflows. This collaboration aims to provide biotech and biopharma sponsors with advanced AI-driven capabilities to enhance study startup efficiency. Biorasi will leverage Ryght AI's platform for real-time insights on site performance and recruitment metrics, improving cost efficiency and reducing startup delays. The partnership focuses on dermatology, oncology, neurology, and nephrology studies, offering refined enrollment forecasts and targeted engagement with high-capacity sites.
AD
Why It's Important?
The partnership between Ryght AI and Biorasi represents a significant advancement in clinical trial management, potentially reducing costs and improving efficiency in the pharmaceutical industry. By utilizing AI-driven digital twins, sponsors can make more informed decisions about site selection and patient recruitment, minimizing delays and enhancing trial outcomes. This collaboration could lead to faster development of new treatments and therapies, benefiting patients and healthcare providers. The integration of AI technology in clinical trials also highlights the growing importance of digital solutions in transforming healthcare research and operations.
What's Next?
Ryght AI and Biorasi will continue to deploy AI technology across various therapeutic areas, optimizing site selection and recruitment processes. The partnership may expand to include additional specialties and collaborations with leading institutions. As AI technology evolves, further enhancements in clinical trial feasibility and efficiency are expected, potentially leading to broader adoption of digital solutions in the healthcare industry. The success of this partnership could inspire similar collaborations, driving innovation and improving patient access to clinical trials.